The treatment with NLRP3 selective inhibitors could mitigate NAFLD and fibrosis in the model of methionine-choline-deficient (MCD) diet-fed mice [27,28]. This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatotic liver disease.